Recent advances of GOLM1 in hepatocellular carcinoma

References

• FornerA, ReigM, BruixJ. Hepatocellular carcinoma. Lancet391(10127), 1301–1314 (2018).
   PubMed Web of Science ®Google Scholar
• LiH, ZhangP, LuoJet al. Chondroitin sulfate-linked prodrug nanoparticles target the Golgi apparatus for cancer metastasis treatment. ACS Nano13(8), 9386–9396 (2019).
   PubMed Web of Science ®Google Scholar
• YuRY, XingL, CuiPFet al. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and brefeldin A for suppression of tumor metastasis. Biomater. Sci.6(8), 2144–2155 (2018).
   PubMed Web of Science ®Google Scholar
• SaiWL, YaoM, ShenSJet al. Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation. Hepatobiliary Pancreat. Dis. Int.doi:10.1016/j.hbpd.2020.02.009 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• LiuY, ZhouS, ShiJet al. c-Myc transactivates GP73 and promotes metastasis of hepatocellular carcinoma cells through GP73-mediated MMP-7 trafficking in a mildly hypoxic microenvironment. Oncogenesis8(10), 58 (2019).
   PubMedGoogle Scholar
• GaiX, TangB, LiuFet al. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3beta/MMPs. J. Genet. Genomics46(5), 235–245 (2019).
   PubMed Web of Science ®Google Scholar
• KeMY, WuXN, ZhangY, WangS, LvY, DongJ. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma. J. Transl. Med.17(1), 140 (2019).
   PubMedGoogle Scholar
• KladneyRD, BullaGA, GuoLet al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene249(1–2), 53–65 (2000).
   PubMed Web of Science ®Google Scholar
• ZhouY, LiL, HuL, PengT. Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol. Biol. Rep.38(3), 1457–1462 (2011).
   PubMed Web of Science ®Google Scholar
• XiaY, ZhangY, ShenM, XuH, LiZ, HeN. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif.52(2), e12538 (2019).
   PubMed Web of Science ®Google Scholar
• BaMC, LongH, TangYQ, CuiSZ. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int. J. Clin. Exp. Pathol.5(9), 874–881 (2012).
   PubMed Web of Science ®Google Scholar
• IftikharR, KladneyRD, HavliogluNet al. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol.99(6), 1087–1095 (2004).
   PubMed Web of Science ®Google Scholar
• KladneyRD, TollefsonAE, WoldWS, FimmelCJ. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology301(2), 236–246 (2002).
   PubMed Web of Science ®Google Scholar
• PuriS, BachertC, FimmelCJ, LinstedtAD. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic3(9), 641–653 (2002).
   PubMed Web of Science ®Google Scholar
• BachertC, FimmelC, LinstedtAD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic8(10), 1415–1423 (2007).
   PubMed Web of Science ®Google Scholar
• WrightLM, YongS, PickenMM, RockeyD, FimmelCJ. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int. J. Clin. Exp. Pathol.2(1), 34–47 (2009).
   PubMed Web of Science ®Google Scholar
• ShiY, ChenJ, LiLet al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol. Cancer Res. Treat.10(3), 287–294 (2011).
   PubMed Web of Science ®Google Scholar
• MaoY, YangH, XuHet al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut59(12), 1687–1693 (2010).
   PubMed Web of Science ®Google Scholar
• ZhouY, YinX, YingJ, ZhangB. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer12, 17 (2012).
   PubMed Web of Science ®Google Scholar
• TianL, WangY, XuDet al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int. J. Cancer129(8), 1923–1931 (2011).
   PubMed Web of Science ®Google Scholar
• HuJS, WuDW, LiangS, MiaoXY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med. Oncol.27(2), 339–345 (2010).
   PubMed Web of Science ®Google Scholar
• MarreroJA, RomanoPR, NikolaevaOet al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol.43(6), 1007–1012 (2005).
   PubMed Web of Science ®Google Scholar
• ZhaoY, ZhangL, HuoLet al. Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma. Int. J. Biol. Markers33(4), 439–446 (2018).
   PubMed Web of Science ®Google Scholar
• LiuT, YaoM, LiuSet al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget8(10), 16498–16506 (2017).
   PubMedGoogle Scholar
• YangJ, LiJ, DaiWet al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp. Ther. Med.9(4), 1413–1420 (2015).
   PubMed Web of Science ®Google Scholar
• SunY, YangH, MaoYet al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J. Gastroenterol. Hepatol.26(7), 1207–1212 (2011).
   PubMed Web of Science ®Google Scholar
• ChenX, WangY, TaoJet al. mTORC1 up-regulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in mice. Gastroenterology149(3), 741–752 e714 (2015).
   PubMed Web of Science ®Google Scholar
• DongY, ZhengQ, WangZet al. Higher matrix stiffness as an independent initiator triggers epithelial–mesenchymal transition and facilitates HCC metastasis. J. Hematol. Oncol.12(1), 112 (2019).
   PubMed Web of Science ®Google Scholar
• BaoYX, CaoQ, YangYet al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn. Pathol.8, 197 (2013).
   PubMed Web of Science ®Google Scholar
• YangY, LiuQ, ZhangHet al. Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial–mesenchymal transition in hepatocellular carcinoma. Oncol. Rep.37(2), 1182–1188 (2017).
   PubMed Web of Science ®Google Scholar
• YeQH, ZhuWW, ZhangJBet al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell30(3), 444–458 (2016).
   PubMed Web of Science ®Google Scholar
• LiuY, ZhangX, SunTet al. Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget7(16), 21404–21415 (2016).
   PubMedGoogle Scholar
• JinD, TaoJ, LiDet al. Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget6(32), 33523–33533 (2015).
   PubMedGoogle Scholar
• ShahM, HuangD, BlickTet al. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE7(1), e29615 (2012).
   PubMed Web of Science ®Google Scholar
• OsakoY, SekiN, KitaYet al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int. J. Oncol.49(6), 2255–2264 (2016).
   PubMed Web of Science ®Google Scholar
• ZhangS, GeW, ZouGet al. MiR-382 targets GOLM1 to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Am. J. Cancer Res.8(1), 120–131 (2018).
   PubMed Web of Science ®Google Scholar
• ZhaoJ, XuT, WangF, CaiW, ChenL. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73. Biomed. Pharmacother.90, 744–751 (2017).
   PubMed Web of Science ®Google Scholar
• ZhouYY, JiangJC, YouJ, ZhouLF. Effect of Golgi phosphoprotein 2 (GOLPH2/GP73) on autophagy in human hepatocellular carcinoma HepG2 cells. Tumour Biol.36(5), 3399–3406 (2015).
   PubMedGoogle Scholar
• ZhangYL, ZhangYC, HanWet al. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J. Gastroenterol.20(32), 11287–11296 (2014).
   PubMed Web of Science ®Google Scholar
• ZhaoN, GuoM, WangK, ZhangC, LiuX. Identification of pan-cancer prognostic biomarkers through integration of multi-omics data. Front. Bioeng. Biotechnol.8, 268 (2020).
   PubMed Web of Science ®Google Scholar
• DanieleA, DivellaR, QuarantaMet al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. Clin. Biochem.47(3), 184–190 (2014).
   PubMed Web of Science ®Google Scholar
• ChenMH, JanYH, ChangPMet al. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann. Surg. Oncol.20(Suppl. 3), S616–S624 (2013).
   PubMedGoogle Scholar
• RienerMO, StennerF, LiewenHet al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology49(5), 1602–1609 (2009).
   PubMed Web of Science ®Google Scholar
• HannHW, WangM, HafnerJet al. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark.7(6), 269–273 (2010).
   PubMed Web of Science ®Google Scholar
• MaoYL, YangHY, XuHFet al. [Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study]. Zhonghua Yi Xue Za Zhi88(14), 948–951 (2008).
   PubMedGoogle Scholar
• AiN, LiuW, LiZG, JiH, LiB, YangG. High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. Oncol. Lett.14(4), 3953–3958 (2017).
   PubMed Web of Science ®Google Scholar
• AndoE, KuromatsuR, TanakaMet al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J. Clin. Gastroenterol.40(10), 942–948 (2006).
   PubMed Web of Science ®Google Scholar
• ShimJH, YoonDL, HanSet al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann. Surg. Oncol.19(12), 3687–3696 (2012).
   PubMed Web of Science ®Google Scholar
• LiangH, Ai-JunJ, Ji-ZongZet al. Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma. Anticancer Drugs30(2), 186–194 (2019).
   PubMed Web of Science ®Google Scholar
• NishimuraT, IwakabeK, SekimotoMet al. Distinct role of antigen-specific T helper Type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med.190(5), 617–627 (1999).
   PubMed Web of Science ®Google Scholar
• JennerRG, TownsendMJ, JacksonIet al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. Proc. Natl Acad. Sci. USA106(42), 17876–17881 (2009).
   PubMed Web of Science ®Google Scholar
• CorthayA, SkovsethDK, LundinKUet al. Primary antitumor immune response mediated by CD4+ T cells. Immunity22(3), 371–383 (2005).
   PubMed Web of Science ®Google Scholar
• PaluckaK, BanchereauJ. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer12(4), 265–277 (2012).
   PubMed Web of Science ®Google Scholar
• KimHJ, CantorH. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res.2(2), 91–98 (2014).
   PubMed Web of Science ®Google Scholar
• TangQF, JiQ, TangYet al. Golgi phosphoprotein 2 down-regulates the Th1 response in human gastric cancer cells by suppressing IL-12A. Asian Pac. J. Cancer Prev.14(10), 5747–5751 (2013).
   PubMedGoogle Scholar
• KimHJ, LvD, ZhangY, PengT, MaX. Golgi phosphoprotein 2 in physiology and in diseases. Cell Biosci.2(1), 31 (2012).
   PubMedGoogle Scholar
• ZhangX, ZhuC, WangTet al. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog.13(4), e1006321 (2017).
   PubMed Web of Science ®Google Scholar
• ZhangW, ZhangJ, ZhangZet al. Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6/STAT3/PD-L1 pathway in bladder cancer. Transl. Oncol.12(3), 485–492 (2019).
   PubMed Web of Science ®Google Scholar
• WolfleSJ, StrebovskyJ, BartzHet al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol.41(2), 413–424 (2011).
   PubMed Web of Science ®Google Scholar
• SongTL, NairismagiML, LaurensiaYet al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood132(11), 1146–1158 (2018).
   PubMed Web of Science ®Google Scholar
• WangY, LiuT, HuangPet al. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget6(15), 13564–13578 (2015).
   PubMedGoogle Scholar
• ZhangX, MengS, ZhangRet al. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget7(20), 29346–29358 (2016).
   PubMedGoogle Scholar